915707-65-2

Usage

Uses

Used in Chemical Research:
(4-Bromo-1-methyl-1H-pyrazol-3-yl)methanol is used as a research compound for its unique molecular structure and reactivity, allowing for exploration in various chemical reactions and interactions.
Used in Pharmaceutical Development:
(4-Bromo-1-methyl-1H-pyrazol-3-yl)methanol is used as a pharmaceutical intermediate due to its potential to be incorporated into the synthesis of new drug molecules, contributing to the development of novel therapeutic agents.
Used in Chemical Synthesis:
(4-Bromo-1-methyl-1H-pyrazol-3-yl)methanol is used as a synthetic building block for creating more complex molecules, which may have applications in various industries, including materials science and specialty chemicals.

InChI:InChI=1/C5H7BrN2O/c1-8-2-4(6)5(3-9)7-8/h2,9H,3H2,1H3

Upstream product

• 1383575-45-8 4-bromo-3-(bromomethyl)-1-methyl-1H-pyrazole 
• 5775-82-6 4-bromo-1,3-dimethyl-1H-pyrazole 
• 211738-66-8 4-bromo-1-methyl-1H-pyrazole-3-carboxylic acid methyl ester 
• 84547-86-4 4-bromo-1-methyl-1H-pyrazole-3-carboxylic acid 

Downstream Products

• 1383572-91-5 9-(4,6-dimethylpyrimidin-2-yl)-4-((1-methyl-4-phenyl-1H-pyrazol-3-yl)methyl)-1,4,9-triazaspiro[5.5]undecan-5-one 
• 1350323-52-2 (4-{3-[(1S)-1-(2-Chloro-3-fluoro-6-methoxyphenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-1-methyl-1H-pyrazol-3-yl)methanol 
• 1350323-66-8 1-(4-{3-[(1S)-1-(2-Chloro-3-fluoro-6-methoxyphenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-1-methyl-1H-pyrazol-3-yl)methanamine 

Relevant academic research and scientific papers

PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES

A compound compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A′ and A″ are independently O, C═O, C—R′ or N—R″, where R′ and R″ may independently be H, amino, —NR7COR6, COR6, —CONR7R8, C1-C6 alkyl, or hydroxy(C1-C6 alkyl), and R″ may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A′ and A″ is O or C═O; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), formyl, heteroaryl, heterocyclic, —COR6, —OCOR6, —COOR6, —NR7COR6, —CONR7R8, and —(CH2)n—W, where W is cyano, hydroxy, C3-C8 cycloalkyl, —SO2NR7R8, and —SO2—R9, where R9 is C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, hydroxy, or C1-C6 alkyl; X is C—R3 or N, where R3 may be H or C1-C6 alkyl; R4 and R5 are independently H, amino, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R6, R7 and R8 are each independently H, C1-C6 alkyl, C1-C4 alkoxy(C1-C6 alkyl), or C3-C8 cycloalkyl, said C1-C6 alkyl is optionally substituted by halo, CN or hydroxy; or, R7 and R8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C1-C6 alkyl; and, n is 0, 1, 2 or 3. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF

A compound represented by Formula [1] (in the formula, Z1 represents N, CH, or the like; X1 represents NH or the like; R1 represents a heteroaryl group or the like; each of R2, R3, and R4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R5 represents a heteroaryl group or the like) or salt thereof.

Di/tri-aza-spiro-C9-C11alkanes

The invention relates to compounds of the formula I [in-line-formulae]A-D-C(R1)2—B??(I),[/in-line-formulae] in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

DI/TRI-AZA-SPIRO-C9-C11ALKANES

The invention relates to compounds of the formula I A-D-C(R1)2-B (I), in which A and B are aromatic ring systems and wherein D is selected from the groups D1 to D5 and the other substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

Fused Bicyclic Kinase Inhibitors

Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.